Dr. Llovet on Efficacy of Namodenoson in Child-Pugh B HCC

Video

In Partnership With:

Josep M. Llovet, MD, discusses a phase II, double-blind, placebo-controlled trial examining the efficacy and safety of namodenoson, an A3 adenosine receptor agonist, as a second-line treatment for patients with Child-Pugh B advanced hepatocellular carcinoma.

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses a phase II, double-blind, placebo-controlled trial examining the efficacy and safety of namodenoson (CF102), an A3 adenosine receptor agonist (A3AR), as a second-line treatment for patients with Child-Pugh B advanced hepatocellular carcinoma (HCC).

In patients with HCC, Child-Pugh B stands for a classification that defines the status of liver failure, Llovet explains.

Prior to this trial, the actions and mechanisms of namodenoson in patients with Child-Pugh B HCC were unknown because all the drugs had been tested in Child-Pugh A patients, according to Llovet. As a result, patients who have Child-Pugh B HCC do not have a standard frontline therapy. Most of the TKIs are toxic in these patients, Llovet explains. Namodenoson has a tolerable safety profile, according to Llovet, and the drug is only being used on Child-Pugh B patients with more preserved liver function.

Results showed that the median overall survival was 4.1 months with namodenoson and 4.3 months in placebo in the intent-to-treat population. Moreover, the median progression-free survival was 2.6 months with namodenoson and 1.9 months with placebo.

Related Videos
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
Susan C. Modesitt, MD, FACOG, FACS, professor, Department of Gynecology and Obstetrics, director, Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine
Nikhil A. Gopal, MD
Hans C. Lee, MD
Manish A. Shah, MD
Jobelle Baldonado, MD
Alexey Danilov, MD, PhD,